Duorui Pharmaceutical released its 2026 interim report, with total operating revenue of 95.66 million yuan, down 10.24% year-on-year, and net profit attributable to the parent of 11.53 million yuan. Net cash flow from operating activities was negative 44.43 million yuan, a decrease of 17.80 million yuan year-on-year. The company's asset-liability ratio was 46.58%, gross margin was 11.20%, ROE was 1.75%, and diluted earnings per share was 0.15 yuan. The number of shareholders was 6,628, and the top ten shareholders held 69.19% of the total share capital.
Tibet Duo Rui Pharmaceutical Co.Ltd.Net profit of 11.53 million yuan with revenue down 10.24% and negative operating cash flow.